SGAM
VIVO

Smith Group Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Smith Group Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-180
Closed -$4K – 403
2021
Q2 		$4K Sell
180
-300
-63% -$6.36K ﹤0.01% 350
2021
Q1 		$13K Buy
+480
New +$11.4K ﹤0.01% 240

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Smith Group Asset Management's VIVO Position: Q3 2021 in Review

Smith Group Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2021, closing a stake of 180 shares — an estimated $4K sold.

Smith Group Asset Management first reported a position in VIVO in Q1 2021 and held it in 2 quarters. The position peaked at $13K in Q1 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q3 2021.

  • Smith Group Asset Management reported no remaining Meridian Bioscience Inc position as of Q3 2021 after selling out during the quarter.
  • Smith Group Asset Management sold 180 Meridian Bioscience Inc shares in Q3 2021, an estimated $4K.
  • Smith Group Asset Management first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 2 quarters.
  • Smith Group Asset Management's Meridian Bioscience Inc position peaked at $13K in Q1 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.